Publication:
Therapeutic potential of topical administration of siRNAs against HIF-1α for corneal neovascularization.

dc.contributor.authorPeral, Assumpta
dc.contributor.authorMateo, Jesus
dc.contributor.authorDomínguez-Godínez, Carmen O
dc.contributor.authorCarracedo, Gonzalo
dc.contributor.authorGómez, Jose Antonio
dc.contributor.authorCrooke, Almudena
dc.contributor.authorPintor, Jesús
dc.contributor.funderMinisterio de Ciencia e Innovación (España)es_ES
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)es_ES
dc.date.accessioned2023-09-07T14:09:47Z
dc.date.available2023-09-07T14:09:47Z
dc.date.issued2022-06
dc.description.abstractGiven the implications of the problem of neovascularization on ocular health, as well as the growth in the number of cases, the purpose of the present study has been testing the efficacy of siRNAs (small interfering RNA) designed to silence Hypoxia Inducible Factor -1α (HIF-1α) and to demonstrate that their use stops neovascularization in a model of corneal burn. Corneal wounds in the limbic zone were made in the eyes of New Zealand white rabbits. Topical applications of siRNAs were done the next day to the wound for four consecutive days and eyes were examined with a slit lamp. Evaluation of neovascularization progress was done by analyzing images by ImageJTM and to determine the neovascular area in Matlab ® was used. At the same time, a rabbit corneal cell line was used for in vitro study of hypoxia exposure and Western blot analysis of the cell's extracts were done. Under normal cell culture oxygenation, the expression of HIF-1α was lower than that observed under hypoxic conditions. After 2 h of hypoxia, there was a significant increase in the HIF-1α expression, effect that was maintained up to 6 h. The increased in HIF-1α was mimicked by a cell permeable prolyl-4-hydroxylase inhibitor. Cobalt chloride showed no capacity to increase HIF-1α in vitro. The effect of three different siRNA on HIF-1α was tested after 4 h of hypoxia. siRNA#1 was able to silence 80% of HIF-1α expression, siRNA#2 and siRNA#3 reduce the expression in 45% and 40% respectively. In addition, the three siRNA were tested in a corneal model of neovascularization. scrambledsiRNA#2 was the most effective inhibitor of blood vessel production, followed by siRNA#3 and siRNA#1. Compared to the scrambled siRNA (100% of blood vessel generation), siRNA#2 blocked the presence of blood vessels by 83 ± 2%, siRNA#3 inhibited 45 ± 7% and siRNA#1 only inhibited 18 ± 5%. The necessary time to observe the 50% of effect showed values of NV50 of 10.2 ± 2.4 days for the scrambled siRNA, 9.1 ± 1.4 for siRNA#1, 6.5 ± 1.85 for siRNA#2 and 4.8 ± 1.8 days for siRNA#3. In conclusion, the topical application of siRNA towards HIF-1α seems to be an effective and reliable method to stop neovascularization.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis work was supported by a grant from Ministerio de Ciencia e Innovación (SAF2010-16024 and SAF2013-44416-R) and RETICS (RD12/0034/0003), and a grant from the Instituto de Salud Carlos III of Spain and Fondo Europeo de Desarrollo Regional (FEDER, “Una manera de hacer Europa”) (FIS-FEDER PI07-1168 to J. Mateo)es_ES
dc.format.page109036es_ES
dc.format.volume219es_ES
dc.identifier.citationExp Eye Res . 2022 Jun;219:109036es_ES
dc.identifier.doi10.1016/j.exer.2022.109036es_ES
dc.identifier.e-issn1096-0007es_ES
dc.identifier.journalExperimental eye researches_ES
dc.identifier.pubmedID35367249es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/16432
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/SAF2010-16024es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/SAF2013-44416-Res_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RD12/0034/0003es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/FIS-FEDER/PI07-1168es_ES
dc.relation.publisherversion10.1016/j.exer.2022.109036es_ES
dc.repisalud.institucionCNICes_ES
dc.repisalud.orgCNICCNIC::Unidades técnicas::Imagen Avanzadaes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshCorneal Neovascularizationes_ES
dc.subject.meshAdministration, Topicales_ES
dc.subject.meshAnimalses_ES
dc.subject.meshCell Hypoxiaes_ES
dc.subject.meshHypoxiaes_ES
dc.subject.meshHypoxia-Inducible Factor 1, alpha Subunites_ES
dc.subject.meshNeovascularization, Pathologices_ES
dc.subject.meshRNA, Small Interferinges_ES
dc.subject.meshRabbitses_ES
dc.subject.meshVascular Endothelial Growth Factor Aes_ES
dc.titleTherapeutic potential of topical administration of siRNAs against HIF-1α for corneal neovascularization.es_ES
dc.typejournal articlees_ES
dc.type.hasVersionCVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication87474fa8-0391-4061-976d-4576907ea30d
relation.isAuthorOfPublication.latestForDiscovery87474fa8-0391-4061-976d-4576907ea30d

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Therapeutic potential of topical_Exp Eye Res_2022.pdf
Size:
772.21 KB
Format:
Adobe Portable Document Format
Description:
Versión aprobada